ArticlemBio2023
Immune Response Modulation by Pseudomonas aeruginosa Persister Cells.
Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 32 citations in OpenAlex.
- Antibiotic exposure and recovery of persister states influence virulence phenotypes in Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- Mechanisms underlying pyogenic bacterial infections of the skin.Archives of microbiology · 2026Review
- Identification of a novel gene inAntimicrobial agents and chemotherapy · 2026Article
- High-throughput bioprinted 3D cultures for probing host-pathogen interactions in bioinspired microenvironments.RSC applied polymers · 2026Article
- Staphylococcus aureus Extracellular Vesicles Enhance PslE-Mediated Pathogenesis in Pseudomonas aeruginosa.MicrobiologyOpen · 2026Article
- The small non-coding RNA sRNA102 regulatesFrontiers in cellular and infection microbiology · 2026Article
- Salmonella enterica persister cells exhibit distinct susceptibility profiles following exposure to human serum and macrophages.PloS one · 2026Article
- The Role of Talaromyces Marneffei Binding To CD86 in the CD86-CTLA4 Regulatory Pathway.Current microbiology · 2025Article
- Article
- Cell-to-Cell and Patient-to-Patient Variability in Antimicrobial Resistance.Microorganisms · 2025Review
- Review
- Immune system dynamics in response to Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Review
- Antimicrobial Activity ofAntibiotics (Basel, Switzerland) · 2025Article
- Review
- Harnessing hypoxia: bacterial adaptation and chronic infection in cystic fibrosis.FEMS microbiology reviews · 2025Review
- Synoviocyte-chondrocyte triculture model for early-stage PTOA: fibronectin fragment-induced catabolic effectsFrontiers in bioengineering and biotechnology · 2025Article
- Molecular characteristics and antibiotic resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa in Nanning, China.BMC microbiology · 2024Article
- Tracking the progeny of bacterial persisters using a CRISPR-based genomic recorder.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Mutation ofMicrobiology spectrum · 2024Article
- Persistence and Culturability ofAntibiotics (Basel, Switzerland) · 2024Article
Corrections and comments
- Update of
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial persister cells-a metabolically dormant subpopulation tolerant to antimicrobials-contribute to chronic infections and are thought to evade host immunity. In this work, we studied the ability of Pseudomonas aeruginosa persister cells to withstand host innate immunity. We found that persister cells resist MAC-mediated killing by the complement system despite being bound by complement protein C3b at levels similar to regular vegetative cells, in part due to reduced bound C5b, and are engulfed at a lower rate (10- to 100-fold), even following opsonization. Once engulfed, persister cells resist killing and, contrary to regular vegetative cells which induce a M1 favored (CD80
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.